GATA2
GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
Overview
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Bortezomib and Fasudil. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes genetic literature 0.89, literature 0.98, genetic association 0.82, somatic mutation 0.95, animal model 0.57). IntOGen calls it a driver in 5 cohorts (3 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Head and Neck Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
- 1 · What it is
GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.
- 2 · What goes wrong in cancer
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'.
- 3 · How drugs use it
No product in this corpus aims at GATA2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:4171 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23769 (protein name, function text, keywords and locations (REST API)); CIViC gene GATA2 (2 evidence items, 0 assertions, 2 variants; diseases: Acute Myeloid Leukaemia, Lung Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000179348 (association with cancer (MONDO_0004992) 0.84; per-cancer scores at or above 0.5: prostate cancer 0.57, acute myeloid leukaemia 0.76, skin cancer 0.54, myelodysplastic syndrome 0.77, myeloproliferative neoplasm 0.80, lung cancer 0.53 (GraphQL API, CC0)); IntOGen GATA2 (driver in 5 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'. Location: Nucleus (UniProt). Locus 3q21.3 (HGNC).
- Leukaemia: Open Targets association 0.80 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.80 with myeloproliferative neoplasm (MONDO_0020076)
- Myelodysplastic syndromes / neoplasms: Open Targets association 0.77 with myelodysplastic syndrome (MONDO_0018881)
- Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"GATA2" OR ABSTRACT:"GATA2" OR TITLE:"GATA binding protein 2" OR ABSTRACT:"GATA binding protein 2" OR TITLE:"Endothelial transcription factor GATA-2" OR ABSTRACT:"Endothelial transcription factor GATA-2" OR TITLE:"NFE1B" OR ABSTRACT:"NFE1B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GATA2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFANCA
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetSRSF2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetSETBP1
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
- TargetGATA1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetPRKCB
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetU2AF1
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).